Ten Bridge Communications

An exciting and well-deserved moment for #TBCPartner Orca Bio, which was recently honored with the Fierce Life Sciences Innovation Award for Biotech Innovation of the Year!   The recognition highlights Orca’s lead investigational therapy for multiple forms of leukemia and the company's commitment to pushing the boundaries of what’s possible for patients and moving science forward.   Fierce Life Sciences Events

Biotech startups need a communications partner that shares their sense of urgency. Founders are under more pressure than ever to show their path to delivering value for investors. We understand this urgency because we’ve seen it first-hand, partnering alongside 100+ early-stage innovators that have needed to do just that. We operate as extensions of our clients’ teams, helping them create compelling scientific narratives that clearly show the path from breakthrough to treatment. This commitment to creating immediate and continuous impact is at the center of NewCo Studio. Why are we the right partner for seed and Series A biotechs? - Science Savvy: Our Ph.D. trained science communicators get to the heart of your innovation narrative - Distinctive Brand and Design: Our embedded creative team develops brands to meet your needs today, while providing a platform to grow with you - Flexible Scoping: We’re positioned to meet you where you are, for projects large and small Have a communications need for your early-stage company? Reach out to us today. https://lnkd.in/e-ggSgmv

Congratulations to #TBCPartner Tenaya Therapeutics on the company's late breaking presentation at #AHA25. The data demonstrated durable changes in multiple parameters of disease for patients with MYBPC3-associated hypertrophic cardiomyopathy (HCM).   These findings represent meaningful progress towards delivering potentially curative therapies that address the underlying drivers of heart disease to even more patients.

Congratulations to #TBCPartner Syndeio Biosciences on being named to C&EN's 10 Start-Ups to Watch list!   Syndeio is pioneering a new approach to engaging neurons so that a single drug dose triggers lasting biological changes, opening new possibilities for creating rapid-acting, safe and effective therapies.

Partnering with more than 100 early-stage biotech pioneers since our founding, we’re evangelists about the power of a stand-out brand and narrative even in our clients’ earliest stages. We’re also pragmatists. We know that for startups, investing in a brand had better pay dividends right away, supporting your strategy and accelerating your success. That’s why we launched the NewCo Studio at Ten Bridge, our concentrated offering scaled for startups.    Based in Boston, the NewCo Studio team of Ph.D.-trained science communicators, biotech-native designers, former industry journalists and company strategists provides leading early companies with what they need – investor decks, message platforms, leadership and visibility programs, websites large or small. We support clients on a single project, a full communications program, or something in between.   Interested in learning more? Check out the offering on our website: https://lnkd.in/e-ggSgmv

With #ASH2025 on the horizon, preparations are in full swing as excitement builds for this year’s presentations on the latest data and research developments in hematology.   With just under a month until the conference, #TBCPartners Orca Bio, Secura Bio, Inc. and PureTech Health's founded entity Gallop Oncology are slated to present new clinical data, progress that continues to move the field forward for patients in need of better treatment options.   American Society of Hematology

Exciting momentum at #TBCPartner Syndeio Biosciences: Aaron Koenig MD has joined as Chief Medical Officer. Aaron’s addition strengthens Syndeio’s leadership in developing next-generation synapse-targeting therapies for psychiatric, cognitive and neurodegenerative conditions. The company’s lead program is in Phase 2 trials for major depressive disorder with planning underway for an upcoming study in Alzheimer’s. Congratulations to the Syndeio team on this step forward and continued progress ahead.

Recently, we wrapped up one of our favorite times on the TBC calendar – offsite week! This is a much-needed time for us to take a step back from our day to day, bond as a team and think about what’s next for the company. This year’s focus was around the energy we bring to our clients, our work and the broader biotech community. Some highlights include: 🔸 2nd Annual Charlie Awards: We handed out awards for Oxygen, Fuel and Heat – the three essential ingredients for stoking the fire we bring to our work 🔸 Special guest Laura Shawver: #TBCPartner Laura Shawver spoke with the team about what she sees in the industry today and her guiding principles as a leader in the industry 🔸 Improv Asylum: Norm Laviolette and Jared Littlejohn stopped by for some improv and lessons on how we can build off one another in our work 🔸 Volunteering at Women's Lunch Place: We spent a morning prepping and serving meals with our friends at Women’s Lunch Place While there will always be elements of our industry beyond our control, what we can control is the energy we bring to our work every day. A special thank you to our partners and our team for making last week’s offsite such a success.

Congratulations to #TBCPartner Parabilis Medicines on their groundbreaking data presentation at #ESMO25. Parabilis set out to create extraordinary medicines for patients, and they are showing that they are on their way to doing just that. In their first clinical data from their Phase 1/2 trial, Parabilis showed that their investigational lead program FOG-001 is the first therapeutic to directly inhibit the β-catenin:TCF transcription factor complex in the cancer-driving Wnt pathway, long considered “undruggable.” A remarkable milestone on the path to transforming cancer treatment.    Congratulations again to the entire Parabilis team; your commitment to the best possible medicines for patients is inspiring.

Why now? Why us? Partnering with early-stage companies that are wrestling with these questions has been a part of our DNA since the very beginning, which is why we’re excited to announce the launch of NewCo Studio, our tailored offering for startups driving scientific innovation forward. Launching a new biotech takes both short-term clarity and long-term vision to chart the path for investors and ultimately reach people waiting for new treatments. Whether interest rates are low or high, public markets are frothy or facing headwinds, this will always be the case. From shaping your scientific story and investor pitch to building a mission-driven brand or splash-page website, our goal is to meet innovators where they are as they shape the future of medicine. Does this sound like you? Check out our site to see what NewCo Studio can offer: https://lnkd.in/e-ggSgmv